Bionanocompósitos quitosana/montmorilonita como um sistema de liberação controlada do ibuprofeno.

Abstract

Chitosan / montmorillonite bionanocomposite films were prepared by the solvent evaporation method, with the aim of immobilizing the drug ibuprofen (IBU) and delaying their release when subjected to a medium that simulates the environment of the gastrointestinal tract. The effects of the presence of montmorillonite, in different mass proportions (50, 20 and 10%), on the morphological and physical properties of the films were studied. X - ray diffracttion (XRD), infrared spectroscopy (FTIR), scanning electron microscopy (SEM), swelling and in vitro controlled release were perfomed. The results indicated that the methodology adopted allowed to produce dense and uniform films, and that the incorporation of montmorillonite with different mass proportions to the system led to the formation of bionanocomposites with orderly intercalated morphology, disordered tending to exfoliation and partially exfoliated, resulting in variations in encapsulation efficiency and degree of swelling of films. The crystallinity of the systems decreased with the incorporation of the drug and when subjected to the in vitro release test in fluids that simulated the environment of the gastrointestinal tract at pH 1.2 (stomach), IBU release occurred by erosion of the matrix and at pH 7.2 (gut) by diffusion. However, in both, the release behavior was of the Fickian type. Among the systems studied, the QCL10IBU showed a slower release rate due to a greater accommodation of the IBU molecules in the galleries of montmorillonite, possibly related to their disordered intercalated morphology tending to exfoliate, their higher degree of crystallinity and encapsulation efficiency. Therefore, in this study, the methodology used was adequate for the synthesis of chitosan / montmorillonite bionanocomposite films with good encapsulation efficiency and with controlled release characteristics of the drug, indicating that these systems are promising in the oral IBU administration.